NASDAQ
No price data available for this timeframe.
Alnylam Pharmaceuticals, Inc. (ALNY) has a consensus Buy rating from 52 analysts with an average price target of $454.27, representing +55.9% upside from the current price of $291.37.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| May 1, 2026 | Unknown | Morgan Stanley | $370.00 | $301.45 | +22.74% |
| May 1, 2026 | Unknown | Bernstein | $447.00 | $302.85 | +47.60% |
| Feb 17, 2026 | Unknown | Canaccord Genuity | $429.00 | $314.40 | +36.45% |
| Feb 13, 2026 | Unknown | Morgan Stanley | $360.00 | $313.75 | +14.74% |
| Feb 13, 2026 | Unknown | Bernstein | $451.00 | $312.43 | +44.35% |
Jun 4, 2026 | Maintained | HC Wainwright & Co. | Buy | Buy |
May 5, 2026 | Maintained | HC Wainwright & Co. | Buy | Buy |
May 1, 2026 | Maintained | Wells Fargo | Equal Weight | Equal Weight |
May 1, 2026 | Maintained | RBC Capital | Outperform | Outperform |
Apr 13, 2026 | Maintained | Truist Securities | Buy | Buy |